Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

336
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
336
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partial rescue of the full-field electroretinogram in patients with RPE65-related retinal dystrophy following gene augmentation therapy with voretigene neparvovec-rzyl.

Documenta ophthalmologica. Advances in ophthalmology·2024
Same author

Aflibercept for the treatment of neovascular age-related macular degeneration.

Drugs of today (Barcelona, Spain : 1998)·2012
Same author

A therapeutic challenge in AIDS-associated viral retinitis.

Eye (London, England)·2011
Same author

Iris nodules associated with infectious uveitis.

The British journal of ophthalmology·2002
Same author

Clinicopathologic correlation of fluorescein and indocyanine green angiography in exudative age-related macular degeneration.

Retina (Philadelphia, Pa.)·2000
Same author

Prevalence of serologic evidence of cat scratch disease in patients with neuroretinitis.

Ophthalmology·2000

Related Experiment Video

Updated: Apr 18, 2026

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

1.5K

Aflibercept: an update on recent milestones achieved.

N V Palejwala1, A K Lauer2

  • 1Retina Vitreous Division, Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.

Drugs of Today (Barcelona, Spain : 1998)
|January 15, 2015
PubMed
Summary

Intravitreal anti-VEGF medications, including aflibercept, have transformed retinal disease treatment. These therapies significantly improve vision in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME).

Keywords:
AfliberceptBranch retinal vein occlusionDiabetic macular edemaMacular edemaNeovascular wet age-related macular degenerationVEGF Trap-Eye

More Related Videos

Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
06:46

Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

Published on: July 25, 2025

1.6K
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.5K

Related Experiment Videos

Last Updated: Apr 18, 2026

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

1.5K
Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse
06:46

Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

Published on: July 25, 2025

1.6K
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.5K

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Background:

  • Intravitreal anti-VEGF agents have revolutionized retinal disease management over the past decade.
  • Pegaptanib, ranibizumab, and bevacizumab improved visual acuity in age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Purpose of the Study:

  • To evaluate the role and effectiveness of aflibercept, a newer anti-VEGF drug, in treating retinal vascular diseases.
  • To compare aflibercept's efficacy with existing treatments like ranibizumab and bevacizumab.

Main Methods:

  • Clinical trials assessing visual acuity and treatment outcomes.
  • Pharmacological analysis of aflibercept's mechanism of action, targeting all VEGF isoforms and placental growth factor.

Main Results:

  • Aflibercept demonstrated comparable effectiveness to existing anti-VEGF therapies in clinical trials.
  • Aflibercept is now a key treatment option for neovascular AMD.
  • Aflibercept is emerging as a significant therapeutic choice for DME and RVO.

Conclusions:

  • Aflibercept represents a valuable addition to the therapeutic arsenal for retinal vascular diseases.
  • The continued development of anti-VEGF therapies offers improved visual outcomes for patients with AMD, DME, and RVO.